Navigation Links
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
Date:5/14/2009

FREMONT, Calif., May 14 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "siRNA Therapeutics for Prevention of Ocular and Inner Ear Sensory Cells Death," at the DxRx Summit: Nucleic Acid Diagnostics & Therapeutics. The event was held May 12-13, 2009 in Boston, MA.

Dr. Feinstein presented data demonstrating that synthetic, chemically-modified 19-bp siRNAs, including PF 04523655 currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD), enter cells in the retina of the eye and exert their therapeutic effects while avoiding non-specific activation of the toll-like receptor 3 (TLR3) - the effect reported for other synthetic siRNAs. Similar data for QPI-1007, Quark's proprietary siRNA composition, were also reported. QPI-1007 was demonstrated to confer effective ocular neuroprotection and is currently in late-stage IND-enabling studies.

In addition to studies in the eye, Dr. Feinstein also reported results demonstrating effective delivery of synthetic siRNAs to the inner ear, which resulted in protection of hearing epithelium from ototoxic and noise-induced damage. These studies were performed in collaboration with Prof. Jayakrishna Ambati, University of Kentucky College of Medicine, Lexington, KY; Prof. Ann Logan, University of Birmingham, UK; Prof. Adriana Di Polo, University of Montreal; and Prof. Richard Salvi, SUNY University at Buffalo.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "Results from the studies presented at DxRx demonstrate our successful track record in discovering and advancing industry-leading siRNA product candidates. Our strong position
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
5. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
11. Vion Pharmaceuticals Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... ... therapy for knee osteoarthritis is an important part of knee pain treatment. ... doing what they want or need to do. The patient may have trouble getting in ... exercise regime may be limited by the pain in their knee. When a patient sees ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... can be a very messy experience, especially when cracking eggs. Cracking an egg is ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2
... 26 Daniel S. Dueber, CEO of Coast Independent Review ... Investigations of the House Energy and Commerce Committee in the ... the Government Accountability Office (GAO) in a clandestine sting operation ... out despite the absence of proof that Coast had committed ...
... free radicals, researchers say , , THURSDAY, March 26 ... influence children,s lung growth and function, as well ... say University of Southern California researchers. , "Many ... genetic variation and environmental exposures such as tobacco ...
... Boston Scientific Corporation (NYSE: BSX ) today ... news announcements at the 58th Annual Scientific Session of ... runs from March 28-31 in Orlando, Florida. "We are ... from the landmark SYNTAX study, the only randomized trial ...
... Group, Inc. (NYSE Amex: QGP ) ( ... RedChip Companies Inc. to enhance its investor relations outreach ... in broadening visibility for emerging growth companies as well ... comprehensive platform of media services," said Noel J. Guillama, ...
... GUANGZHOU, China, March 26 /PRNewswire-Asia / -- ... Medicine" or "the Company"), a,developer and a ... Chinese medicines ("TCM"),nutritional and dietary-supplements, medical devices, ... China ("PRC"), today reported outstanding,financial results for ...
... is Alcohol Awareness MonthSEYMOUR, Tenn., March 26 Six ... on alcohol, according to the National Center on Addiction ... binge drinking in women,s colleges increased by 124 percent ... in need of but have not received treatment for ...
Cached Medicine News:Health News:Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful 2Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Boston Scientific Announces Schedule For ACC 2009 2Health News:Boston Scientific Announces Schedule For ACC 2009 3Health News:Boston Scientific Announces Schedule For ACC 2009 4Health News:Boston Scientific Announces Schedule For ACC 2009 5Health News:Boston Scientific Announces Schedule For ACC 2009 6Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 2Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 2Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 4Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 5Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 6Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 7Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 8Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 9Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 10Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 11Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 2Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 3
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Cloud-based Veeva CRM Now Deployed in Over 20 European ... Customer Summit kicking off this morning in Philadelphia, Veeva Systems ... Since Veeva,s official expansion into Europe in April 2010, the ... than 35 life sciences companies across 20+ different European markets. ...
... AB (OMX: MVIR), a research-based specialty pharmaceutical company focused ... Henric Juserius to be the new head of the ... for Medivir,s pharmaceutical marketing and sales, will join the ... the management team. Henric Juserius has a ...
Cached Medicine Technology:Veeva Systems Announces Dramatic Growth in Europe 2Veeva Systems Announces Dramatic Growth in Europe 3Veeva Systems Announces Dramatic Growth in Europe 4New Executive Vice President Commercial Appointed 2
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 3.5V halogen source....
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: